Paul M Mertes1, Charles Tacquard1, Georges Andreu2, Daniel Kientz3, Sylvie Gross4, Lucile Malard4, Christian Drouet5, Monique Carlier6, Christian Gachet3, Imad Sandid7, Karim Boudjedir7. 1. Department of Anesthesia and Intensive Care, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 2. Institut National de Transfusion Sanguine, Paris, France. 3. Etablissement Français du Sang Grand Est, Strasbourg, France. 4. Etablissement Français du Sang, La Plaine Saint-Denis, France. 5. INSERM U1016, CNRS UMR8104, Institut Cochin, Université Paris-Descartes, Paris, France. 6. Agence Régionale de Santé Grand Est, Châlons en Champagne, France. 7. French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France.
Abstract
BACKGROUND: Among labile blood products, platelet concentrates (PCs) are the leading cause of hypersensitivity transfusion reactions (HTRs). These reactions often lead to interruption of PC transfusion and can result in a prolonged transfusion process leading to significant morbidity and use of premedication and close monitoring for patients with a history of allergic transfusion reactions. The French hemovigilance database is one of the largest standardized databases providing information on HTRs following administration of labile blood products. In this study, we analyzed this database to assess the relative risk of HTR for each type of PC. STUDY DESIGN AND METHODS: HTRs following PC transfusion were retrospectively extracted from the e-Fit Hemovigilance database of the French National Agency for Medicines and Health Products Safety (ANSM). Frequencies were calculated using the number of specific PCs transfused. RESULTS: Between 2008 and 2014, the overall estimated incidence of HTRs following PC administration was calculated at 232 HTRs per 100,000 PCs transfused. The rate of HTRs was significantly higher with apheresis PC (337/100,000) than with buffy-coat PC (94/100,000). Platelets in additive solutions (PAS) were associated with a significantly lower frequency of HTRs when compared with PCs in native plasma. Amotosalen/UVA- PCs (APCs and BCPCs) which are always in PAS in France, exhibited the lowest frequency of HTRs when compared with their corresponding PCs in native plasma or in PAS (p < 10-7 in all comparisons). CONCLUSION: Our results showed that the type of PC and its processing may have an impact on the risk of HTR.
BACKGROUND: Among labile blood products, platelet concentrates (PCs) are the leading cause of hypersensitivity transfusion reactions (HTRs). These reactions often lead to interruption of PC transfusion and can result in a prolonged transfusion process leading to significant morbidity and use of premedication and close monitoring for patients with a history of allergic transfusion reactions. The French hemovigilance database is one of the largest standardized databases providing information on HTRs following administration of labile blood products. In this study, we analyzed this database to assess the relative risk of HTR for each type of PC. STUDY DESIGN AND METHODS: HTRs following PC transfusion were retrospectively extracted from the e-Fit Hemovigilance database of the French National Agency for Medicines and Health Products Safety (ANSM). Frequencies were calculated using the number of specific PCs transfused. RESULTS: Between 2008 and 2014, the overall estimated incidence of HTRs following PC administration was calculated at 232 HTRs per 100,000 PCs transfused. The rate of HTRs was significantly higher with apheresis PC (337/100,000) than with buffy-coat PC (94/100,000). Platelets in additive solutions (PAS) were associated with a significantly lower frequency of HTRs when compared with PCs in native plasma. Amotosalen/UVA- PCs (APCs and BCPCs) which are always in PAS in France, exhibited the lowest frequency of HTRs when compared with their corresponding PCs in native plasma or in PAS (p < 10-7 in all comparisons). CONCLUSION: Our results showed that the type of PC and its processing may have an impact on the risk of HTR.
Authors: Sanjida J Mowla; Ian T Kracalik; Mathew R P Sapiano; Lynne O'Hearn; Chester Andrzejewski; Sridhar V Basavaraju Journal: Transfus Med Rev Date: 2021-04-02
Authors: Edward L Snyder; Allison P Wheeler; Majed Refaai; Claudia S Cohn; Jessica Poisson; Magali Fontaine; Mary Sehl; Ajay K Nooka; Lynne Uhl; Philip Spinella; Maly Fenelus; Darla Liles; Thomas Coyle; Joanne Becker; Michael Jeng; Eric A Gehrie; Bryan R Spencer; Pampee Young; Andrew Johnson; Jennifer J O'Brien; Gary J Schiller; John D Roback; Elizabeth Malynn; Ronald Jackups; Scott T Avecilla; Jin-Sying Lin; Kathy Liu; Stanley Bentow; Ho-Lan Peng; Jeanne Varrone; Richard J Benjamin; Laurence M Corash Journal: Transfusion Date: 2022-06-24 Impact factor: 3.337
Authors: Sanjida J Mowla; Mathew R P Sapiano; Jefferson M Jones; James J Berger; Sridhar V Basavaraju Journal: Transfusion Date: 2021-08-01 Impact factor: 3.337